Meningitis and sepsis caused by serogroup B meningococcus are two severe 
diseases that still cause significant mortality. To date there is no universal 
vaccine that prevents these diseases. In this work, five antigens discovered by 
reverse vaccinology were expressed in a form suitable for large-scale 
manufacturing and formulated with adjuvants suitable for human use. The vaccine 
adjuvanted by aluminum hydroxide induced bactericidal antibodies in mice against 
78% of a panel of 85 meningococcal strains representative of the global 
population diversity. The strain coverage could be increased to 90% and above by 
the addition of CpG oligonucleotides or by using MF59 as adjuvant. The vaccine 
has the potential to conquer one of the most devastating diseases of childhood.